Private-equity firms to buy iNova from Valeant

8 June 2017 - Deborah Wilkes

Archived

Valeant Pharmaceuticals International is selling its iNova Pharmaceuticals business to two private-equity firms for USD930 million in cash.

Click tags below for more information on topics:

iNova

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: